公开(公告)号：US20250064808A1

公开(公告)日：2025-02-27

申请号：US18942238

申请日：2024-11-08

Applicant: The Regents of the University of California

Inventor： Michael Karin ,  Hongxu Xian

IPC: A61K31/517 ,  A61P37/06 ,  C12N15/113

Abstract: Provided herein are methods for treating a disease or condition associated with one or more of: mtDNA fragmentation; cytostolic Ox-mtDNA; mtDNA release; or Casp1 activation and IL-1β production by administering an effective amount of an inhibitor of human flap endonuclease-1 (FEN1). These diseases include without limitation, an inflammatory or a neurodegenerative disease, such as Alzheimer's, disease, Parkinson's disease, atherosclerosis, NASH, asthma, inflammatory bowel disease, melanoma, metabolic pathologies, including obesity, type 2 diabetes, atherosclerosis, inflammatory bowel diseases, gout, and periodic fevers.

公开(公告)号：US12234271B2

公开(公告)日：2025-02-25

申请号：US17016003

申请日：2020-09-09

Applicant: Synthorx, Inc.

Inventor： Jerod Ptacin ,  Carolina E. Caffaro ,  Marcos Milla

IPC: C07K14/55 ,  A61P37/06 ,  C07D487/04

Abstract: Disclosed herein are compositions, kits, and methods comprising interleukin (IL) conjugates (e.g., IL-2 conjugates) useful for the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).

公开(公告)号：US12233080B2

公开(公告)日：2025-02-25

申请号：US17037079

申请日：2020-09-29

Applicant: Northwestern University

Inventor： Stephen F. Murphy ,  Praveen Thumbikat ,  Anthony Schaeffer

IPC: A61K39/085 ,  A61K9/00 ,  A61K31/7032 ,  A61K35/00 ,  A61K35/741 ,  A61P19/02 ,  A61P29/00 ,  A61P37/06

Abstract: Provided herein are compositions comprising lipotechoic acid (LTA) and methods of use thereof for immune modulation. In particular, compositions comprising S. epidermidis lipotechoic Acid (SELTA) are provided, as well as method of use thereof for the treatment of immune—(e.g., autoimmune) and inflammation-related conditions and diseases (e.g., chronic pelvic pain syndrome (CPPS), arthritis, etc.).

公开(公告)号：US20250059547A1

公开(公告)日：2025-02-20

申请号：US18722941

申请日：2022-12-23

Applicant: Secarna Pharmaceuticals GmbH & Co. KG

Inventor： Marta Lucia DE LOS REYES ,  Frank JASCHINSKI ,  Sven MICHEL ,  Anna URI

IPC: C12N15/113 ,  A61K45/06 ,  A61P37/06

Abstract: The present invention refers to oligonucleotide consisting of 12 to 20 nucleotides comprising at least one modified nucleotide hybridizing with a nucleic acid sequence of NLR family pyrin domain containing 3 (NLRP3) and a pharmaceutical composition 5 comprising such oligonucleotide together with a pharmaceutically acceptable carrier, excipient and/or dilutant to inhibit the expression of NLRP3 for example for preventing and/or treating an inflammatory disease.

公开(公告)号：US20250057920A1

公开(公告)日：2025-02-20

申请号：US18249932

申请日：2022-03-22

Applicant: CHIANG MAI UNIVERSITY ,  SURANAREE UNIVERSITY OF TECHNOLOGY

Inventor： Chatchai TAYAPIWATANA ,  Umpa YASAMUT ,  Montarop YAMABHAI ,  Vannajan Sanghiran LEE

IPC: A61K38/21 ,  A61P37/06 ,  C12N15/85

Abstract: A modified or bioengineered protein of a modified interferon gamma (IFN-γ) related to at least one modification. Preferably, the modified IFN-γ comprises at least one modification of an amino acid located at a position of 27 to 40 of a sequence as setting forth in SEQ ID NO. 1. The modified IFN-γ is capable of initiating cellular signaling towards an immune response upon being administered to a subject.

公开(公告)号：US12227558B2

公开(公告)日：2025-02-18

申请号：US18167121

申请日：2023-02-10

Applicant: Ohio State Innovation Foundation

Inventor： Thomas J. Magliery ,  Mikhail M. Dikov ,  David Carbone ,  Nicholas Long ,  Brandon Sullivan ,  Elena Tchekneva

IPC: A61K38/00 ,  A61P35/00 ,  A61P37/06 ,  C07K14/705

Abstract: Described herein are Notch-modulating peptides (including monomers and multimers) capable of increasing or decreasing an immune response in a subject, compositions comprising the peptides, and methods of use thereof.

公开(公告)号：US20250051446A1

公开(公告)日：2025-02-13

申请号：US18463454

申请日：2023-09-08

Applicant: OSE Immunotherapeutics

Inventor： Bernard Vanhove

IPC: C07K16/28 ,  A61K9/00 ,  A61K38/47 ,  A61K39/00 ,  A61K39/395 ,  A61K47/60 ,  A61P37/06

Abstract: The present invention pertains to a novel and advantageous dosage regimen for a humanized pegylated monovalent anti-CD28 Fab′ antibody fragment, called “FR104”. This dosage regimen consists of between 0.05 and 1.5 mg/kg body weight of FR104, at a dosing schedule of once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks or once every 6 weeks, once every 7 weeks, once every 8 weeks or once every more than 8 weeks.

公开(公告)号：US20250051414A1

公开(公告)日：2025-02-13

申请号：US18570542

申请日：2022-06-30

Applicant: The Regents of the University of California

Inventor： Aaron S. MEYER

IPC: C07K14/55 ,  A61K38/00 ,  A61P37/06 ,  C07K14/54

Abstract: The present disclosure provides a multivalent biomolecule comprising three or more covalently linked common γ-chain receptor cytokines (e.g., IL-2, IL-4, IL-7, IL-9, IL-15 or IL-21, or an immunologically active fragment thereof). In one embodiment, the common γ-chain receptor cytokines in the multivalent biomolecule are expressed as Fc fusion proteins with an IgG1 Fc. The multivalent biomolecule presented herein can be used to activate or suppress immune responses in a subject.

公开(公告)号：US20250051286A1

公开(公告)日：2025-02-13

申请号：US18721175

申请日：2022-12-16

Applicant: ORIXA THERAPEUTICS LLC

Inventor： Adam Seth HAEBERLE ,  Matteo PANZA ,  James Bernard KRAMER ,  Zahra ASSAR-NOSSONI ,  Matt SIMON

IPC: C07D233/38 ,  A61K31/4025 ,  A61K31/4174 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/53 ,  A61K45/06 ,  A61P1/04 ,  A61P37/06 ,  A61P43/00 ,  C07D207/50 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D417/12

Abstract: Disclosed herein are novel small molecules that can be used therapeutically to treat ailments and diseases associated with an over-active or undesired immune response. Specific embodiments include inhibitors of Proteinase 3 (PR3) and Human Neutrophil Elastase (HNE) and methods for their synthesis and use. The agents can be used to treat alpha-1 antitrypsin deficiency and other ailments related to neutrophil activity.

公开(公告)号：US12221482B2

公开(公告)日：2025-02-11

申请号：US16909553

申请日：2020-06-23

Applicant: UCL Business Ltd

Inventor： Martin Pule ,  Paul Maciocia ,  Ben Grimshaw

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/06 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/86 ,  A61K35/00 ,  A61K38/00

Abstract: The invention relates to protein-based T-cell receptor knockdown, and its use in T-cell therapies.